Vern C. Juel, M.D. – Congenital myasthenic syndrome

Submitted By:
[email protected]
Published Date:
January 25, 2020

Access Program Information

<p>This is a continuing project to provide 3,4 diaminopyridine (DAP) under a treatment-use IND to patients with Lambert-Eaton myasthenic syndrome (LEMS) and congenital myasthenic syndrome (CMS).</p>